Type 2 diabetes (T2D) and heart failure (HF) are rapidly increasing in the US population and often coexist. The American Heart Association, the American College of Cardiology, and the Heart Failure Society of America have released guidelines recommending sodium-glucose cotransporter 2 (SGLT2) inhibitors, which are considered antidiabetic drugs, as first-line treatment for heart failure regardless of T2D diagnosis, unless contraindicated.
Large-scale clinical trials, such as EMPA-REG, demonstrated a reduction in HF hospitalization and cardiovascular mortality compared with placebo. CANVAS and DECLARE-TIMI 58 further demonstrated the benefits of SGLT2 inhibitors in an HF population. Additional clinical trials, such as SCORED, EMPA-KIDNEY, and SOLOIST, are examining benefit of SGLT2 inhibitors in this patient population with comorbidities.
Dr Deepak Bhatt of Icahn School of Medicine at Mount Sinai Health System discusses the emerging clinical data establishing SGLT2 inhibitors as valuable, but frequently underprescribed, in the management of heart failure patients with T2D.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Management of Heart Failure in Patients With Type 2 Diabetes - Medscape - Feb 06, 2023.
Comments